Elevance Health Reports First Quarter 2024 Results

Go back to Elevance Health Reports First Quarter 2024 Results

Elevance (ELV) PT Raised to $605 at UBS

April 19, 2024 6:36 AM EDT

UBS analyst AJ Rice raised the price target on Elevance (NYSE: ELV) to $605.00 (from $585.00) while maintaining a Buy rating.

The analyst comments "ELV provided a few more details around its recently announced CDR partnership, noting that the care delivery entity will start... More

Elevance (ELV) PT Raised to $600 at Wells Fargo

April 19, 2024 5:57 AM EDT

Wells Fargo analyst Stephen Baxter raised the price target on Elevance (NYSE: ELV) to $600.00 (from $557.00) while maintaining a Overweight rating.

The analyst comments "ELV's 1Q24 results were strong and earnings quality appears high. Story remains fairly clean from our perspective. Continued growth... More

Elevance Health (ELV) hikes 2024 earnings outlook, shares climb

April 18, 2024 7:03 AM EDT

Shares of Elevance Health (NYSE: ELV) rose 3% after the health insurance provider topped earnings expectations for the fiscal Q1 and raised its outlook for the full fiscal 2024.

The companys first-quarter earnings per share (EPS) came in at $10.64, topping consensus estimates of $10.48. Revenue was... More